FDA New Analysis on PD Psychosis Treatment

Posted on by Phil Franchina

On September 20, 2018, the FDA recently released results of a new analysis...see more finding no new or unexpected safety risks associated with Nuplazid. The new analysis was initiated because of concerns raised in the media last spring, and reassures patients that they should continue to take Nuplazid as prescribed by their physician. The FDA report highlights a number of important concepts

Read More

APDA Awards $1.7 Million in Cutting-Edge Research Grants

Posted on by Phil Franchina

The American Parkinson Disease Association Awards More Than $1.7 Million in Cutting-Edge Research Grants From Biomarkers to the Microbiome,...see more Some of the Smartest Parkinson’s Research to be Funded in 2018-2019 NEW YORK, NY – September 6, 2018 – The American Parkinson Disease Association (APDA) has awarded more than $1.7 million to support cutting-edge Parkinson’s disease […]

Read More

Promising results from APDA-funded LRRK2 research

Posted on by Phil Franchina

On July 25, 2018, the APDA Center for Advanced Research at the University of...see more Pittsburgh, led by the Center’s Director (and APDA Scientific Advisory Board member), Dr. J. Timothy Greenamyre, published results of a study highlighting the role of Leucine-rich Repeat Kinase (LRRK2) in the development of Parkinson’s disease.

Read More